Clinical Trial Update: Safety Evaluation of Intravenous Talineuren (TLN) in Parkinson's Disease-affected Patients [Phase 1]

View source ↗

Summary

This clinical trial update reports that the Phase 1 safety evaluation of intravenous Talineuren (TLN) in Parkinson's disease patients has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Talineuren (TLN) (Talineuren)

Snippet

Sponsor: InnoMedica Schweiz AG | Conditions: Parkinson Disease | Phase 1 | Status: TERMINATED